U.S. FDA Grants Tentative Approval of Yutrepia (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

The U.S. FDA has granted tentative approval to Yutrepia (treprostinil) inhalation powder for treating PAH and PH-ILD, pending the expiration of a competing product's exclusivity. Liquidia plans to challenge the FDA's grant of exclusivity to United Therapeutics for Tyvaso DPI to expedite Yutrepia's full approval.